A Comprehensive Clinical Assessment of the LumiraDx International Normalized Ratio (INR) Assay for Point-of-Care Monitoring in Anticoagulation Therapy
The LumiraDx INR Test showed a good performance compared to laboratory-based testing and provided opportunity for rapid and patient-centric care. Owing to an increasing positive bias for INR > 3.5, confirmation with laboratory INR measurements may be required.
Authors
- Sakina Loonat
- Lara Noble (ORCID: https://orcid.org/0000-0002-4661-9023)
- Lesley Scott (ORCID: https://orcid.org/0000-0001-6573-9525)
- Elise Schapkaitz (ORCID: https://orcid.org/0000-0002-1534-2930)
- Barry Jacobson (ORCID: https://orcid.org/0000-0001-6981-3112)
- Wendy Stevens (ORCID: https://orcid.org/0000-0002-1684-908X)
- Riffat Munir (ORCID: https://orcid.org/0000-0001-5007-5295)
- Melanie Mc Cree (ORCID: https://orcid.org/0000-0001-9317-7435)
- Nazeer Ali
Institutions
- National Health Laboratory Service (ZA)
- University of the Witwatersrand (ZA)
- Johannesburg Hospital (ZA)
- Chris Hani Baragwanath Hospital (ZA)
Publication Details
- Journal
- Diagnostics
- Published
- 2024-11-28
- DOI
- https://doi.org/10.3390/diagnostics14232683
- Citations
- 2
- Primary Topic
- Clinical Laboratory Practices and Quality Control
- Type
- article
- Field-Weighted Citation Impact
- 0.65
Funders
- Bill and Melinda Gates Foundation